Tobacco Documents Online

Idle JR, Millburn P, Williams RT. Taurine conjugates as metabolites of arylacetic acids in the ferret. Xenobiot'-c=_ 1978;8:253-264. Idle JR, Sever PS. Collecting it. World Medicine 1978; (Sept. 6). r• Lancaster R, Mahgoub A, Idle J-R, Smith RL. Alic;:c_i: hydroxylation phenotype and the hypotensive response to debrisoquine Proc 7th Internat Congr Pharmacol 1978:2789. Mahgoub A, Idle JR, Smith RL. A population and familial study the defective alicyclic hydroxylation of debrisoquine amo^_ Egyptians. Xenobiotica 1978;9:51-56. Sloan TP, Idle JR, Lancaster R, Smith RL. Alicvc:ic hydroxylation phenotype status and the elimination kinetics of debrisoquine. Proc 7th Internat Con.gr Pharmaco: 1978:2866. Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith Polymorphism of carbon oxidation of drugs and cl'_nica: implications. Br Med J 1978;2:655-657. Smith RL, Idle JR, Mahgoub A, Sloan TP, Lancaster R. Genetica_'_v determined defects of oxidation at carbon centres of drues. Lancet 1978;i:943-944. 10 CTR_ HN 011067

1979 Andoh B, Idle JR, Mahgoub A, Sloan TP, Smith RL, Woolhouse ":`:. Polymorphic hydroxylation of debrisoquine in Ghanaians. Br _ Pharmacol 1979;66:431P. - Idle JR, Mahgoub A, Angelo MM, Dring LG, Lancaster R, Smith RL. 14 The metabolism of [ Cj-debrisoquine in man. Br J Clin Pharmacol 1979;7:257:266. Idle JR, Ritchie JC, Smith RL. Oxidation phenotype and metiamide metabolism. Br J Pharmacol 1979;66;432P. Idle JR, Sloan TP, Smith RL, Wakile LA. Application of the phenotyped panel approach to the detection of polymorphisW of drug oxidation. Br J Pharmacol 1979;66:430-431P. Idle JR, Smith RL. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Dzug Metab Rev 1979;9:301-317. Kitchen I, Trembla; J, Andre J, Dring LG, Idle JR, Sr„1 tl-: P.L, Llilliams P.T. Interindividual and interspecies variation '_.. the metabolism of the hallucinogen 4-methoxy-ampheta;nine. Xenobiotica 1979;9:397-404. Mahgoub A, Idle JR, Smith RL. Geneticallv determined variabilit•~ in drug metabolism: dual slow acet;:lation and drug oxidatiorn traits. Lancet 1979;ii:154. Mutawa M, Islam SI, Idie Jr2. Drug oxidation in phenylketonuria Proc Conference on Paediatric Disease (Kuwait) 1979. 11 V' TR( i i i 01106B

t.:al:ile LA, Sloan TP, Idle JR, Smith RL. Genetic evidence for t.._ involvement of different oxidative mechanisms in d:u: oxidation. J Pharm Pharmacol 1979;31:350-352. ldoolhouse NM,. Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith R:-. Debrisoquine hydroxylation polymorphism among Ghanaians anc caucasians. Clin Pharmacol Ther 1979;26'.584-591. 1980 Andoh B, Idle JR. Sloan TP, Smith RL, Uoolhouse NM. Inter-eth::ic and inter-phenotype differences among Ghanaians anc caucasians in the metabolic hydroxylation of phenytoin. J Clin Pharmacol 1980;9:282-283P. V _ Bababunrni EA, Idle JR, --Mahgoub A, Mbanefo C, Smith RL. Polymorphic hydroxylation of debrisoquine in Nigerians. B: J Clin Pharmacol 1980;9:112-113P. Caldwell J, Idle JR, Smith RL. The amino acid conjugations. :... ExtraheDatic Metabolism of Drur,s and Other Foreitn (TE Gram, ed) pp.453-492, Spectrum Publications, Ne: Yc::: (1980). Chapman PH, Idle JR, Mahgoub A, Mucklow JC, Rawlins MD, Rogers S, Shuster S, Smith RL. 4-Hydroxylation of debrisoquine _- psoriasis. Br J Clin Pharmacol 1980;9:113-114P. Chapman PH, Idle JR, Mahgoub A, Rawlins MD, Smith RL, Shuster S. Drug oxidation in psoriasis. Br J Dermatoi 1980;102:72E. 12 l.r tR F EN 0.! 1OC°9

Danhof M, Breimer D, Sloan TP, Idle JR, Smith RL. Antip,:ri::e metabolite formation in extensive and poor hydroxylators o: debrisoquine. Proc 1st World Conzr Clin Pharmacol (w'emb:ev; 1980. Hetzel MR, Law M, Keai EE, Sloan TP, Idle JR, Smith RL. Is there a genetic component in bronchial carcinoma in smokers' Thorax 1980;35:709. Idle JR. A novel role for taurine. In: Sulphur in Biologv; Ciba Foundation Symposium, No.72, pp.282-284 (1980). Idle JR, Oates NS, Ritchie JC, Shah RR, Sloan TP, Smith RL. Ne_ perspectives of genetic polymorphism in drug metabolisW. Advanced Medicine 1980;16:227-234. Idle JR, Smith RL. Inter-ethnic differences in the metabo'::c disposition of drugs and toxic substances. In: Toxicoloe•: ' the Tropics (RL Smith and EA Bababunmi, eds) pp.239-253. Taylor & Francis Ltd., London (1980). Islam SI, Idle JR. Polymorphic drug oxidation among Saudis. ?:c: 5th Saudi Medical `ieetinQ 1980:101. Islam SI, Idle JR, Smith RL. The polymorphic 4-hydroxvlatio^n o: debrisoquine in a Saudi arab population. Xenobiotica 1980;10:819-825. Mbanefo C, Bababunmi EA, Mahgoub A, Sloan TP, Idle JR, Smith ?.. A study of the debrisoquine hvdroxylation polymorphis:c i.. a Nigerian population. Xenobiotica 1980;10:811-818. 13 ., _ - - - 7 . .. . CTR i i{ i 011070

Mucklow JC, Caraher KT, Idle JR. Rawlins "'J, Sloan TP, Smith R:., Wood P_ The influences of changes of dietary fat on t:e clearance of antipyrine and the 4-hvdroxviation of debrisoquine. Br J Clin Pharmacol 1980;9:283P. Oates NS, Shah RR, Idle JR, Smith RL. On the urinary disposition of phenformin and 4-hydroxy-phenformin 'and their rapid simultaneous measurement. J Pharm Phai-macol 1980;32:7'_:- 732. Price-Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A fami:_r and population study of the genetic polymorohisT. : debrisoquine oxidation in a British white population. J?le-~ Cenet 1980;17:102-105. Ritchie JC, Sloan TP, Idle JR, Smith RL. Toxicologica: implications of polymorphic drug metabolism. In: Environmental Chemicals, Enzvme Function and Human Ciba Foundation Symposium No 76, pp.219-244 (1980). Disease Shai: F.: , Oates NS, ldle JR, Smi", RL. Genetic i-,pairmer,_ phenformin metabolism. Lancet 1980;i:1147. 1981 Al-Dabbagh SG, Idle JR, Smith RL. Animal modelling of humar. polymorphic drug oxidation - the metabolism of deb:isoc,uine and phenacetin in rat inbred strains. J Pharm Pharmacol :98';33:161-164. 14 C T HN 011. 0'r 1

Danhof M, Idle JR, Teunissen M'wE, Sloan T?, Breimer DD, Smith =_. Influence of the -generically controlled deficiency debrisoquine hydroxylation on antipyrine metabol'_-~ formation. PharmacoloQv.1981;22:349-358. Idle JR. Hydroxylation phenotype and hepatocellular carcinoma. In: Druq Reactions and the Liver (M Davis, JM Treger and ? Williams, eds) pp:313-315, Pitman Medical, London (1981). Idle JR, Islam SI. Polymorphism of phenformin 4-hydroxylation i.. Saudi females. Br-J Pharmacoi 1981;72:177-178P. Idle JR, Mahgoub A, Sloan TP, Smith RL, Mbanefo CO, Bababu=i_-.. Some observations of the oxidative phenotype status cf Nigerian patients presenting with cancer. Cancer Let: 1981;11:331-338. Idle JR, Oates NS, Shah RR, Smith RL. Is there a genet:c predisposition to phenformin induced lactic acidosis? Clin Pharmacol 198':;11:418-419P. idle JR, Osikowska B::, Sever PS, Swinbourne FJ. Pitfalls in synthesis and authentication of dopamine 0-sulphates. Pharmacol 1981; )4: 837p. Islam SI, Idle JR. Increased risk from environmental carcinogens in Saudis. Proc 6th Saudi Medical Meetine, 1981. Mitchell SC, Waring RH, Idle JR. Smith RL. Cimetidine pretreatment decreases carbocvsteine sulphoxidation I,, m.:a;.. I R.C.S. Med Sc: ?9E:;9:1028-1029. 15 C T R t11N 0 11072

Oates NS, Shah RR, Idle JR, Smith RL. Phenformin-induced :act'_c acidosis with impaired debrisoquine hydroxvlatior.. :_a^ce_ 1981;i:837-838. H Sloan TP, Idle JR, Smith RL. Influence of the D/Dy alleies regulating debrisoquine oxidation on pheny:o:-: hydroxylation. Clin Pharmacol Ther 1981;29:493-497. Smith RL, Idle JR. Genetic polymorphism in drug oxidation. In: DruR Reactions and the Liver (H Davis, JM Treger and Gilliams, eds) pp.95-104, Pitman Medical, London (1981). Waring RH, Mitchell SC, Idle JR, Smith RL. Geneticai:•: determined impaired drug sulphoxidation. Lancet 1981;i:778. 1982 Hetzel MR, Law M, Keal EE, Sloan TP, Idle JR, Smith RL. inbor-: susceptibility/resistance _to lung cancer. In: Cellular BioloQV of the Lunq pp.448-457, Plenum Publishir:: Corporation, Ne:: York (1982). Islam SI, Idle JR. Drug metabolism in arabs - triennial repor: of the joint Jeddah-London Pharmacogenetics Programme. 7th Saudi Medical Meetine, 1982. Kong I, Devonshire H'~:, Cooper `:, Sloan TP, Idle JP., Smith R:,. The infuence of oxidation phenotype on phenacetin metaboiisr and haemotoxicity. Br J Clir. Pharmacol 1982;13:275-276P. lo CTR _ •N 01.M 0*73'

Kupfer A, Al-Dabbagh SC, Ritchie JC, Idle JR, Smith RL. Spectra'_ binding studies of the polymorphically. metabolised dru2s debrisoquine, sparteine and phenformin by cytochrome ?-45C by normal and hydroxylation deficient rat strains. Biochem Pharmacol 1982;31:3193-3199. Mitchell SC, Idle . JR,Smith RL. The metabolism o: 14 ( C)cimetidine in man Xenobiotica 1982;12:283-292. Mitchell SC, Idle JR, Smith RL. Reductive metabolism of cimetidine sulfoxide in man. Drug Metab Dispos 1982;10:2"0z- 290. Mitchell SC, Ritchie JC, Idle JR, Smith RL. Nature of the polar metabolites of inetiamide and cimetidine in man. Biochem Soc Trans 1982;10:123-124. _ Nadir HH, Al-Dabbagh SC, Idle JR. Elevated serum cholesterol i^ drug-oxidation-deficient rats. Biochem Pharmaco: 1982;31:1665-1668. - Oates NS, Shah P.R, Id:e JR, Smith RL. Genetic polyznorphism c: phenformin 4-hydroxvlation. Clin Pharmacol Ther 1982;32:81- 89. Oram M, Wilson K, Burnett D, Al-Dabbagh SC, Idle JR, Smith R:.. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 1982;23:147-150. 17 CTR HN 011074,

Osikowska BA, Idle JR, Swinbourne FJ, Sever PS. Uneouivoca: synthesis and characterisation of dopamine 3- and ~ sulphates. Biochem Pharmacol 1982;31:2279-2284. Ritchie JC, Idle JR. Population studies of polymorphism in dr__ oxidation and its relevance to carcinogenesis. In: 'r.es; factors in human carcinogenesis B Armstrong 6'B Bartsch eds. IARC Scientific Publications_,:No.39, Lyon (1982). Shah RR, Oates NS, Idle JR, Smith RL. Beta-Blockers and dr.:: oxidation status Lancet 1982;i:508-509. Shah RR, Oates NS, Idle JR, Smith RL. Impaired oxidation cf debrisoquine in patients with perhexiline neuropathy. B- Med J 1982;284:295-299. Waring RH, Mitchell SC, Shah RR, Idle JR, Smith RL. Polymorp:^.i: sulphoxidation of S-carboxymethyl-L-cysteine in man.Bioche^ Pharmacol 1982; 31: 3151-3154 1983 Devonshire HW, Kong I, Cooper M, Sloan TP, Idle JR, Smith .... The contribution of genetically determined oxidaion status to inter-individual variation in phenacetin dispos•:tion.?= _ Clin Pharmacol 1983; 16: 157-166 Evans DAP, Harmer D, Downham DY, Whiblev EJ, idle JR, Ritc'.^.ie .' , Smith RL. The genetic control of sparteine and debrisoquine in man with new methods of anaivsinQz bimodal distributicns J Med Genet 1983: 20: 321-329. 18 C T R H N 0 110 'r''Es'

Idle JR, Hirom PC, Kirkby CA. Effect of the MO:D locus on the biliary metabolites of benzo(a)pyrene in the rat. In: International Gstaad Symposium, September 1983, 37. Idle JR, Oates NS, Shah RR, Smith RL.• Protecting poor metabolisers, a group at high risk of adverse drug reactions. Lancet 1983; 1: 1388. Idle JR, Ritchie JC. Probing genetically variable carcinogen metabolism using drugs. In: Human Carcinogenesis (C Harris and H Autrup, eds) Academic Press, 1983: 857-881. Idle JR, Sever PS. Treatment of angina pectoris with nifedipine. Br Med J 1983; 286: 1978-1979. Oates NS, Shah RR, Idle JR, Smith RL. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther 1983; 34: 827-834. Panayi GS, Hutson G, Shah RR, Mitchell SC, Idle JR, Smith Varing RH. Deficient sulphox.idation status and penicillamine toxicity. Lancet 1983; 1: 414. Ritchie JC, Crothers MJ, Idle JR, Grieg JB, Connors TA, Nikolov IC, Chernozemsky I::. Evidence for an inherited metabo'_ic susceptibility to endemic (Balkan) nephropathy. In: Current research in endemic (Balkan) nenhronathy (S Strahinjic 6V Steefanovic, eds). University Press Nis, 1983: 23-27. 19 CTR HN 011076